Monday, 25 March 2019

Bone Growth Stimulator Market Pipeline Review, 2018- Identify Key Business Opportunities

Market Scenario:
Bone Growth stimulators are devices that are used to boost the healing process during the treatment of the ailments such as spinal fixation, orthopedic fixation. Bone growth stimulators works on all kinds of fractures such as fresh fractures, fractures healing slowly or not at all, fractures with an elevated risk. It can also be used as supportive therapy after surgery on a fracture and in corrective osteotomy.
Global Bone Growth Stimulator Market is expected to grow significantly over the forecast period. The market held a market value of USD 1,213 million in 2017 and is projected to grow at a CAGR of 5.86% over the forecast period.
Bone Growth Stimulator enhances the healing process by stimulating the production of new cells, which will allow your fracture to heal considerably faster. Bone growth stimulators are the perfect treatment approach when patient is not comfortable with the surgical procedure and wants to avoid it. Also, as it fastens the healing process, it helps patients get back to their feet quickly. Bone growth stimulators have revolutionized the treatment of bone fractures and spinal fusions and are becoming an important tool in the healing process. Advantages over surgical procedures, faster recovery time, and increasing patient preference are some of the factors contribute to the growth of the bone growth stimulator market.
Key players:
Arthrex, Inc., Bioventus LLC, Depuy Synthes (A Subsidiary of Johnson & Johnson), DJO Finance LLC, Harvest Technologies (A Terumo BCT Company), Isto Biologics, Medtronic PLC, Orthofix International N.V., Stryker Corporation, and Zimmer Biomet Holdings, Inc. are some of the key players in the global bone growth stimulator market.
Segmentation:
The Global Bone Growth Stimulator Market has been segmented into Product, Application and End user.Based on products, the market has been segmented into, bone growth stimulation devices, bone morphogenetic proteins, platelet-rich plasma, and others. The bone growth stimulation devices segment is further segmented into, external bone growth stimulators, implanted bone growth stimulators, and ultrasonic bone growth stimulators among which external bone growth stimulators include pulsed electromagnetic field devices, capacitive coupling devices, and combined magnetic field devices. The Bone Growth Stimulation Devices segment is expected to account for the largest share in the global bone growth stimulator market in 2017. This large share is majorly attributed to the wider acceptance of the devices, and better patient compliance as compared to other techniques.
On the basis of application, the market has been segmented into spinal fusion surgeries, delayed union & non-union bone fractures, oral and maxillofacial surgeries, and other. The spinal fusion surgeries segment is expected to account for the largest share in the global bone growth stimulator market in 2017.On the basis of end users, the market has been segmented into hospitals & clinics, home care, academic and research institutes, and others. The hospitals & clinics segment is expected to account for the largest share in the global bone growth stimulator market in 2017. At the same time, the increasing establishments of the home care services in the developed and developing countries has led this segment to grow at the fastest rate during the forecast period.
Based on the regions, the market for bone growth stimulator is segmented in to, the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Bone Growth Stimulator Market in the Americas region has further been segmented into North America and South America, where-in the North American market is further divided into the US and Canada. European Bone Growth Stimulator Market has been segmented into Western Europe and Eastern Europe where-in Western Europe region is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Bone Growth Stimulator Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bone growth stimulator market in the Middle East & Africa has been segmented into regions such as the Middle East and Africa.
Regional Market Summary: 
Geographically, the Americas is anticipated to dominate the global bone growth stimulator market owing to the rising prevalence of the orthopaedic and spinal ailments such as bone fractures, and spinal damage among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way. Moreover, increasing rate of the spinal fusion procedures, growing patient population for the orthopaedic fixation procedures, high awareness among American population, high disposable income, are some of the many factors that drive the growth of the bone growth stimulator market in this region.
Europe is expected to hold the second largest market share in the global bone growth stimulator market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the bone growth stimulator market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the bone growth stimulator market during the forecast period.
Browse Complete 130 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bone-growth-stimulator-market-6962


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 22 March 2019

Top trends in Transgenic Animals Market by 2018

Market Scenario:
Transgenic animals carry a foreign gene deliberately inserted into its genome.  The insertion of the foreign DNA into the host body is carried out by the application of recombinant DNA technology. The transmission of the foreign gene is facilitated through the germ line so that every cell of the targeted animal contains the same modified genetic material. In 1997, Rosie (first transgenic cow) was produced with the aim of generating human protein-enriched milk. The milk was nutritionally balanced as compared to the natural bovine milk and was suitably exploited to meet the special nutritional requirements of the geriatric population and babies. Insulin, growth hormone, and anti-blood clotting factors are some of the products that can be effectively obtained from the milk of transgenic cows, sheep, or goats. Growing biotechnology sector followed by rising R&D expenses is estimated to be a major driver for the market growth during the forecast period. In 2016, the revenue generated by the emerging biotech industries across the globe was estimated to be around USD 139.4 billion. Moreover, increasing prevalence of cardiovascular diseases, diabetes, and other disorders along with the rising healthcare expenditures and growing awareness for the transgenic animals is boosting the market growth.
According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. However, stringent FDA policies followed by the high developmental cost and reluctance in the acceptance of transgenic products is estimated to restrain the market growth. The cost of producing a transgenic animal may range from USD 20,000 to USD 300,000.
The market for transgenic animals is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023.
Segmentation
The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.
On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others. On the basis of the techniques, the market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others. On the basis of the consumables, the market is segmented into fluorescent probes, culture media, and others. On the basis of the application, the market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others. On the basis of the model organisms, the market is segmented into mice, rabbit, cows, and others. On the basis of the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.
Key players for transgenic animals market
Cyagen Biosciences, Charles River, Creative-Biolabs, TRANS GENIC INC.., Ltd., Sutter Instrument Company, Bio-Rad Laboratories, Inc., Spinco Biotech Pvt Ltd., Abbott, Thermo Fisher Scientific Inc., Sigma-Aldrich Co., Accumold, and others are some of the major players for transgenic animals market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Plasma Fractionation Market Volume Forecast and Value Chain Analysis 2018

Plasma Fractionation Market Scenario:

In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.

Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.


Global plasma fractionation market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.

Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.
However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.
Segmentation
The global plasma fractionation market is segmented based on product, application, end user, and region.
The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.
Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.
Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.
On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at 1 comment:

Top trends in Optical Imaging Market by 2018

Market Scenario
The global optical imaging market is expected to be of value USD 1.92 Billion in 2023 and to grow at a depict 10% CAGR during the forecast period.  Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Key players
Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V., Agfa-Gevaert N.V.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy share in the global optical imaging market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/optical-imaging-market-6172
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Uterine Sarcoma Market 2018 Share, Trend, Segmentation and Forecast to 2023

Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016. Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.
The market for global uterine sarcoma is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.
Key players
  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • FMC Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • General Electric Company
  • Koninklijke Philips N.V.
  • Siemens Healthcare Private Limited
Segmentation
The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.
On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.
On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.
On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.
Regional Analysis
America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.
Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.
Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.
The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/uterine-sarcoma-market-5131


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Intussusception Market Pipeline Review, 2018- Identify Key Business Opportunities

According to the National health statistics, intussusception affects about 1 in every 1,900 children in the US. Its incidence is more common in children between one to five months, peaking at four to nine months of age, and then gradually declines at around 18 months. Intussusception affects boys and girls, with a ratio of approximately 3:1.
Intussusception, also called bowel obstruction, is a potentially life-threatening condition caused by folding of one part of the intestine into another part, which causes a blockage in the intestine. The blockage hamper the excretion process. Intussusception is dominant in children of age 2 months-2 years. However, adults may also be affected by the intussusception. It commonly occurs where the small and large intestines meet. Additionally, it can occurs due to various causes such as tumors, inflammation, Meckel's diverticulum, duplication, appendix, hyperplasia of Peyer's patches, intestinal surgery, polyps, tumors, inflammation, etc.
It block the blood supply to intestine and causes tissue death. Tissue death can lead to infection, internal bleeding, tearing, damage to the intestines, and peritonitis. The primary symptoms of intussusception include acute abdominal pain, vomiting, nausea, lethargy, blood or mucus in the stools, constipation, etc. The risk factors for intussusception are age, sex, abnormal intestinal formation at birth, a family history, etc.
The developments in the surgery segment, such as minimal invasive laparoscopy surgery, is driving the global intussusception market. The drug segment is, however, suffering from market fragmentation, which has put pressure on the price margins. The loss of patents and the rise of counterfeited drugs has also restricted the market growth. The other market constrains are high cost of surgery and complications of the surgery. Market development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to minimal invasive surgical procedures.
The global intussusception market is expected to reach USD 6.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Key Players in the Global Intussusception Market
Some of the key players profiled in the report are Pfizer, Inc., Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, Bayer AG, FUJIFILM Holdings Corporation, General Electric Company, Shimadzu Corporation, Carestream Health, Bristol-Myers Squibb Company, and others.
Segments of Global Intussusception Market
The global intussusception market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on the type, the market has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others.
Based on the surgery, the market has been segmented as surgery, drugs, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Based on the diagnosis, the market has been segmented as barium enema, ultrasound, X-ray, computerized tomography (CT), and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/intussusception-market-4511
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Wednesday, 20 March 2019

Chemotherapy Market size and Key Trends in terms of volume and value 2018

Market Scenario:
Chemotherapy is excessively used for the treatment of different types of cancer such as lung cancer, bone cancer, blood cancer, etc. The technological advancements in the treatment are further expected to boost the future trajectory of the chemotherapy market.
According to the analysis offered by Market Research Future (MRFR), the global chemotherapy market has been presumed to strike a CAGR of 6.2% during the forecast period 2017 to 2023. Chemotherapy is an effective treatment for cancer which infuses drugs into the bloodstream to target specific cancer sites. The growth trajectory of the market is anticipated to be dominated by the rising burden of the disease.

Emphasis is placed on research & development for bringing more precision and effectiveness. It is prognosticated to have a favorable impact on the expansion of the chemotherapy market. On the flip side, factors such as the high cost of treatment and poor reimbursement policies remain impediments to the market growth. In addition, the side effects of the treatment such as hair loss, hearing impairment, alopecia, etc. are projected to further hinder the proliferation of the chemotherapy market in the upcoming years.
Competitive Dashboard:
Some of the key players profiled in this MRFR report are Sanofi (France), Eli Lilly & Company (U.S.), GlaxoSmithKline (U.K.), Novartis (Germany), Pfizer Inc. (U.S.), ImClone Systems Inc. (U.S.), AstraZeneca (U.K), Schering-Plough (U.S.), Bristol-Myers Squibb , Teva Pharmaceuticals Industries (Japan), F. Hoffmann-La Roche Ltd ( Switzerland), Boehringer Ingelheim (Germany), Merck & Co., Inc. (U.S.), CELGENE CORPORATION (U.S.), Amgen Inc (U.S.), Chemo Espana SL (Spain), Bayer AG (Germany), and Takeda Pharmaceutical Company Limited (Japan).
Market Segmentation:
On the basis of drugs, the global chemotherapy market has been segmented into anti-tumor antibiotics, topoisomerase inhibitors, alkylating agents, antimetabolites, mitotic inhibitors, and others. The alkylating agents segment has been further sub-segmented into mustard gas derivatives, ethylenimines, alkyl sulfonates, hydrazines and triazines, and others. The anti-tumor antibiotics segment is further sub-segmented into anthracyclines and chromomycin. The topoisomerase inhibitors segment has been sub-segmented into Topoisomerase I inhibitors and Topoisomerase II inhibitors.
On the basis of indication, the chemotherapy market has been segmented into lymphoma, leukemia, breast cancer, lung cancer, myeloma, ovarian cancer, sarcoma, and others.
On the basis of the route of drug administration, the global chemotherapy market has been segmented into oral and intravenous.
On the basis of end-user, the chemotherapy market has been segmented into hospitals, research institutes, and others.
Regional Analysis:
By region, the global chemotherapy market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is expected to thrive significantly in the foreseeable future. The rising burden of cancer is poised to dive the expansion of the chemotherapy market in the region over the assessment period. Other factors that are likely to propel the expansion of the regional market are changing lifestyle, advancements in healthcare, rising healthcare expenditure, etc.
Europe is projected to witness considerable growth owing to the availability of funds and government support for research & development. Also, Asia Pacific is likely to flourish during the projection period due to rapid developments in the healthcare sector. It is estimated to strike a comparatively higher CAGR across the review period. Meanwhile, the Middle East & Africa resonates growth opportunities owing to the increasing awareness about the disease.
Industry News:
In May 2018, Advanced Chemotherapy Technologies, North Carolina, has started working on large coin-sized implant for delivering chemo agents into the pancreas.
In September 2018, Alan B. Pearson Regional Cancer Center in Lynchburg announced the installation of Dignicap Cooling System that cools down the scalp by 37 degrees for preventing hair loss during chemotherapy.
In December 2018, a team of experts is reported to work on the development of dry powder for inhaled chemotherapy. The Belgian spin-off project, InhaTarget Therapeutics, aims at treating lung cancer locally.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/chemotherapy-market-5791

Detailed Table of Contents:
Table Of Contents
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
5 Global Chemotherapy Market, By Material
5.1 Introduction
5.1.1 Synthetic Materials
5.1.2 Genetically Engineered Materials
5.1.3 Biologically Derived Materials
5.1.4 Others
...Continued!


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:
Subscribe to: Posts (Atom)